Triple Helix Discovery Engine
Funding Opportunities: Pioneers, Architects & Consolidators
*Funding: Surgery_Surgical Technology, Minimally Invasive & Operating Room of the Future (ORF)
*Venture Capital Companies: Life Science, Health IT & Healthcare Investors
ARCH Venture Partners - (#8 Healthcare Investor 2013) WBT
Finance & Acquisitions: Arch Ventures
*Portfolio Companies: Arch Ventures

Allozyne, Inc.

Parents

*Architects: Biotechnology _Monoclonal, Polyclonal, Bispecific Antibodies & Antibody-Drug Conjugates (ADC)s
*Industry: Washington
*Portfolio Companies: Arch Ventures
Architects: Biotechnology_Proteomics

*Investors’ bet they can create genetically engineered protein drugs with greater capability to bind with targets than today’s antibodies
*Portfolio Companies: Accelerator Corporation
*Quite a few companies have been sprouting up and raising cash in the last couple years with similar notions of developing “bio-superiors” or “bio-betters.” (2010)
Allozyne Acquires Poniard Pharmaceuticals, Finds Backdoor Route to NASDAQ (2011)
Allozyne, graduated from Accelerator raising $30 million in October, 2007
Broad utility in developing improved therapeutic proteins including monoclonal antibodies
Commercialize proprietary technologies developed in the laboratories of Dr. David Tirrell and Dr. William Goddard III., at the C
Consistent approach to specifically modifying recombinant proteins
Enables the manufacturing of proteins into which non-natural amino acids may be incorporated
Improve the efficacy of protein-based therapeutics
Initially focus on developing enhanced formulations of currently approved protein therapeutic products
Poniard Pharmaceuticals Inc and Allozyne Inc Terminate Planned Merger (2011)
Seattle, Washington
The type and specific location of the non-natural amino acid used can be optimized to improve the potency